Life sciences · Journal article
Frontiers in Pharmacology · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Emodin, a natural anthraquinone compound, exhibits anti-inflammatory, antioxidant, and broad-spectrum anti-tumor activities. Studies have shown that Emodin can inhibit the activation and functions of various immune cells, thereby being recognized as an important immunosuppressive agent. In this study, we conducted in vitro experiments to examine the effects of Emodin on the apoptosis, differentiation, and immunosuppressive functions of myeloid-derived suppressor cells (MDSCs), as well as its impacts on the migration, proliferation, and viability of mouse pancreatic cancer H7 cells. Furthermore, we established a mouse orthotopic pancreatic cancer model to evaluate Emodin’s anti-pancreatic cancer effects in vivo and its modulation of immune cell subpopulations. The results revealed that Emodin exerts anti-pancreatic cancer effects through direct inhibition of tumor cells and regulation of MDSCs, although its modulation of the immune microenvironment exhibits concentration-dependent and subset-specific characteristics. These findings suggest that combination therapy and dose optimization are crucial directions for its clinical translation.